Interferon alpha, interferon beta, and interferon gamma have overlapping yet distinct biologic activities.
Interferon alfa, interferon beta og interferon gamma har over- lappende og alligevel adskilte biologiske virkninger.
Subcutaneous and intramuscular administrations of Rebif produce equivalent exposure to interferon beta.
Subkutane og intramuskulære injektioner af Rebif producerer ækvivalente billeder af interferon beta.
Interferon alpha, interferon beta, and interferon gamma have overlapping yet distinct biological activities.
Interferon alfa, interferon beta og interferon gamma har overlappende og alligevel forskellige biologiske virkninger.
The protein in Avonex is made up of exactly the same ingredients as interferon beta that is found in the human body.
Proteinet i Avonex består af nøjagtig samme stoffer som det interferon beta, der findes i menneskets krop.
Interferon beta may cause flu-like symptoms such as headache, fever, chills, muscle and joint pains, fatigue and nausea.
Behandling med interferon beta kan give influenzalignende symptomer så som hovedpine, feber, kulderystelser, led og muskelsmerter, træthed og kvalme.
This assay is limited in that it is sensitive for interferon butlacks specificity for interferon beta.
Denne målemetode begrænses af, at den er følsom for interferon, menmangler specificiteten for interferon beta.
When administered by the subcutaneous orintramuscular routes, serum levels of interferon beta remain low, but are still measurable up to 12 to 24 hours post-dose.
Når stoffet gives subkutant ellerintramuskulært forbliver serum niveauet af interferon beta lavt, men er stadig målbart i op til 12 til 24 timer efter dosis.
The reason for changing the first line of interferon beta or glatimerat acetate in dimethyl fumarate or the teriflunomide: a. serious side effects(documented and reported) b.
Årsagen til at ændre den første linje af interferon beta eller glatimerat acetat i dimethylfumarat eller teriflunomid: en. alvorlige bivirkninger(og dokumenteret) b.
Caution should be used andclose monitoring considered when administering Interferon beta to patients with severe renal failure.
Der bør udvises forsigtighed, ognøje monitorering bør overvejes, når Interferon beta gives til patienter med svært nedsat nyrefunktion.
Active disease despite treatment with one of the drugs: interferon beta, glatiramer acetate, teriflunomid, dimethyl fumarate disease is active and met the criteria for treatment discontinuation with the previously listed drugs.
Aktiv sygdom på trods af behandling med et af lægemidlerne: interferon-beta, glatiramer acetat, teriflunomid, dimethylfumarat sygdom er aktiv og opfylder kriterierne for behandlingsophør med de tidligere anførte lægemidler.
According to available data,some expectant mothers took during pregnancy natalizumab and interferon beta with no harmful effects on the fetus.
Ifølge de foreliggende oplysninger,nogle vordende mødre tog under graviditeten natalizumab og interferon-beta uden skadelige virkninger på fosteret.
According to available data, glatiramer acetate and interferon beta can be used during breastfeeding which can not be said with certainty for other immunomodulatory drugs.
Ifølge de foreliggende data, glatirameracetat og interferon beta kan anvendes under amning, som kan ikke siges med sikkerhed for andre immunmodulerende lægemidler.
Extavia should not be used in people who have a history of hypersensitivity(allergy)to natural or recombinant interferon beta, human albumin or any of the other ingredients.
Extavia må ikke anvendes til patienter, der kan være overfølsomme(allergiske)over for naturligt eller rekombinant interferon beta, humant albumin eller nogen af indholdsstofferne.
The criteria for starting treatment alemtuzumab(II. line)active disease despite treatment with one of the drugs: interferon beta, glatiramer acetate, teriflunomid, dimethyl fumarate(disease is active and met the criteria for treatment discontinuation with the previously listed drugs): progression of relapsing with an increase in EDSS≥1 point during 12 months progression without relapses with increasing≥1 EDSS point during 6 months three relapses during 12 months EDSS< =6.0 absence of pregnancy.
Kriterierne for behandlingens start alemtuzumab(II. linje)aktiv sygdom på trods af behandling med et af lægemidlerne: interferon-beta, glatiramer acetat, teriflunomid, dimethylfumarat(sygdom er aktiv og opfylder kriterierne for behandlingsophør med de tidligere anførte lægemidler): progression af tilbagevendende med en stigning i EDSS ≥1 punkt under 12 måneder progression uden tilbagefald med stigende ≥1 EDSS punkt under 6 måneder tre tilbagefald i løbet af 12 måneder EDSS< 6,0 fravær af graviditet.
In patients with active disease and who did not respond to a full and adequate treatment regime(usually at least one year of treatment)at least one treatment that modifies the course of the disease(interferon beta, glatiramer acetate, teriflunomid, dimethyl fumarate), or when the criteria for the interruption of therapy that.
Hos patienter med aktiv sygdom og som ikke reagerer på en fuldstændig ogtilstrækkelig behandling regime(normalt mindst et års behandling) mindst en behandling, der modificerer sygdomsforløbet(interferon-beta, glatiramer acetat, teriflunomid, dimethylfumarat), eller når kriterierne for afbrydelse af behandlingen, som.
The exact way that Rebif works in MS is not yet known but interferon beta seems to calm the immune system down and prevent relapses of MS.
Det vides endnu ikke med sikkerhed, hvordan Rebif virker ved dissemineret sklerose, men det ser ud til, at interferon- beta dæmper immunsystemet og forhindrer attakker af dissemineret sklerose.
Resultater: 29,
Tid: 0.0425
Sådan bruges "interferon beta" i en sætning
Recently a publication was made by novartis ag regarding interferon beta – 1b.
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
The use of Interferon beta or Glatiramer acetate decreases the rate of relapses.
Glatiramer acetate injection (Copaxone) and interferon beta 1-a (Avonex) are both injectable drugs.
Cases have been reported several weeks to years after starting interferon beta products.
Interferon beta products are more efficacious for the treatment of relapsing-remitting multiple sclerosis.
Interferon beta therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis.
But interferon beta is one of the body’s natural defenses against viral infections.
Interferon beta (IFNb) is well established as first line therapy in relapsing/remitting multiple sclerosis.
In 1993, interferon beta became the first drug approved for the treatment of MS.
English
Deutsch
Español
Suomi
Français
Norsk
عربى
Български
বাংলা
Český
Ελληνικά
עִברִית
हिंदी
Hrvatski
Magyar
Bahasa indonesia
Italiano
日本語
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Nederlands
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt
中文